Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/43140
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Landi, A | - |
dc.contributor.author | Morici, N | - |
dc.contributor.author | VRANCKX, Pascal | - |
dc.contributor.author | Frigoli, E | - |
dc.contributor.author | Bonacchini, L | - |
dc.contributor.author | Omazzi, B | - |
dc.contributor.author | Tresoldi, M | - |
dc.contributor.author | Camponovo, C | - |
dc.contributor.author | Moccetti, T | - |
dc.contributor.author | Valgimigli, M | - |
dc.date.accessioned | 2024-06-13T12:21:12Z | - |
dc.date.available | 2024-06-13T12:21:12Z | - |
dc.date.issued | 2023 | - |
dc.date.submitted | 2024-06-13T12:19:02Z | - |
dc.identifier.citation | JOURNAL OF CARDIOVASCULAR MEDICINE, 24 (12) , p. 920 -930 | - |
dc.identifier.uri | http://hdl.handle.net/1942/43140 | - |
dc.description.abstract | An excessive inflammatory response and a hypercoagulable state are not infrequent in patients with coronavirus disease-2019 (COVID-19) and are associated with adverse clinical outcomes. However, the optimal treatment strategy for COVID-19 patients managed in the out-of-hospital setting is still uncertain. | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.rights | 2023 Italian Federation of Cardiology - I.F.C. All rights reserved. | - |
dc.subject.other | anticoagulant therapy | - |
dc.subject.other | anti-inflammatory therapy | - |
dc.subject.other | colchicine | - |
dc.subject.other | COVID-19 | - |
dc.subject.other | edoxaban | - |
dc.subject.other | SARS-CoV-2 | - |
dc.title | Edoxaban and/or colchicine in outpatients with COVID-19: rationale and design of the CONVINCE trial | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 930 | - |
dc.identifier.issue | 12 | - |
dc.identifier.spage | 920 | - |
dc.identifier.volume | 24 | - |
local.bibliographicCitation.jcat | A1 | - |
local.publisher.place | TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.identifier.doi | 10.2459/JCM.0000000000001556 | - |
dc.identifier.pmid | 37942793 | - |
dc.identifier.isi | 001102568100009 | - |
local.provider.type | Web of Science | - |
local.uhasselt.international | yes | - |
item.contributor | Landi, A | - |
item.contributor | Morici, N | - |
item.contributor | VRANCKX, Pascal | - |
item.contributor | Frigoli, E | - |
item.contributor | Bonacchini, L | - |
item.contributor | Omazzi, B | - |
item.contributor | Tresoldi, M | - |
item.contributor | Camponovo, C | - |
item.contributor | Moccetti, T | - |
item.contributor | Valgimigli, M | - |
item.accessRights | Open Access | - |
item.fullcitation | Landi, A; Morici, N; VRANCKX, Pascal; Frigoli, E; Bonacchini, L; Omazzi, B; Tresoldi, M; Camponovo, C; Moccetti, T & Valgimigli, M (2023) Edoxaban and/or colchicine in outpatients with COVID-19: rationale and design of the CONVINCE trial. In: JOURNAL OF CARDIOVASCULAR MEDICINE, 24 (12) , p. 920 -930. | - |
item.fulltext | With Fulltext | - |
crisitem.journal.issn | 1558-2027 | - |
crisitem.journal.eissn | 1558-2035 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
bb.pdf | Peer-reviewed author version | 1.05 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.